Trials / Completed
CompletedNCT02258074
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nicotinamide | |
| DRUG | Lanthanum Carbonate | |
| DRUG | Placebo (for Nicotinamide) | Sugar pill manufactured to mimic Nicotinamide 750 mg capsule |
| DRUG | Placebo (for lanthanum carbonate) | Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-11-01
- Completion
- 2019-09-01
- First posted
- 2014-10-07
- Last updated
- 2021-08-02
- Results posted
- 2021-07-30
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02258074. Inclusion in this directory is not an endorsement.